Table 1.
Demographics for the cohort with and without early indication biopsies, within the first 14 days post-transplant
| Characteristic | Entire Cohort, N=984 | Grafts with Early Indication Biopsy, n=291 | Grafts without Early Indication Biopsy, n=693 |
|---|---|---|---|
| Recipient characteristics at transplantation | |||
| Age, yr, mean±SD | 54±13 | 54±13 | 54±13 |
| Recipient BMI at time of transplantation, kg/m2, mean±SD | 25.4±4.5 | 25.8±4.7 | 25.2±4.3 |
| Sex, male, n (%) | 598 (61%) | 179 (62%) | 419 (61%) |
| White race, n (%) | 968 (98%) | 299 (100%) | 678 (98%) |
| Pretransplant diabetes mellitus, n (%) | 172 (17%) | 61 (21%) | 111 (16%) |
| Repeat transplantation, n (%) | 153 (16%) | 52 (18%) | 101 (15%) |
| Donor characteristics at transplantation | |||
| Age, yr, mean±SD | 48±15 | 50±15 | 47±15 |
| Sex, male, n (%) | 527 (54%) | 146 (50%) | 381 (55%) |
| Type of donor | |||
| Living donor, n (%) | 57 (6%) | 15 (5%) | 42 (6%) |
| Donation after brain death, n (%) | 774 (79%) | 222 (76%) | 552 (80%) |
| Donation after cardiac death, n (%) | 153 (16%) | 54 (19%) | 99 (14%) |
| Transplant characteristics | |||
| Cold ischemia time, h, mean±SD | 14.2±5.6 | 14.5±5.7 | 14.1±5.6 |
| Asystolic ischemia time, min mean±SD (only in donation after cardiac death donors) | 17.1±10.3 | 18.9±9.9 | 16.2±10.5 |
| Anastomosis time, min, mean±SD | 35.1±8.2 | 35.6±8.1 | 34.9±8.2 |
| Total HLA-A, -B, -DR mismatches, mean±SD | 2.7±1.3 | 3.0±1.3 | 2.6±1.3 |
| Immunosuppression regimen TAC‐MPA‐CS, n (%) | 862 (88%) | 266 (91%) | 596 (86%) |
| Induction therapy, n (%)a | 411 (42%) | 121 (42%) | 290 (42%) |
| Pretransplant donor-specific anti-HLA antibodies, n (%) | 108 (11%) | 54 (19%) | 54 (8%) |
| Delayed graft function | 188 (19%) | 101 (35%) | 87 (13%) |
| Overall survival 1 yr | 93% | 87% | 96% |
| Overall survival 3 yr | 87% | 81% | 90% |
| Overall survival 5 yr | 80% | 71% | 84% |
| Death-censored graft survival 1 yr | 95% | 91% | 97% |
| Death-censored graft survival 3 yr | 92% | 87% | 95% |
| Death-censored graft survival 5 yr | 89% | 82% | 92% |
BMI, body mass index; TAC-MPA-CS, tacrolimus-mycophenolic acid-corticosteroids.
a
Induction agents most often consisted of anti-IL2 receptor blockade (basiliximab, daclizumab) (380 of 411, 93%), other agents included thymoglobulins (6%), alefacept (1%), Igs (0.5%), and rituximab (0.2%).